Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockDiscover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Biocon Ltd (BIOCON) is currently trading at 422.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Biocon is a fully integrated, innovation‑led biopharmaceutical company from India focused on biosimilars, complex biologics, interchangeable insulins, generic formulations, peptides (GLP‑1s) and research/CRDMO services through Syngene with global manufacturing and commercialization reach across North America, Europe and emerging markets. The group is at an operational inflection: major capex is largely complete, operating leverage is beginning to play out, and management highlights margin expansion and cash‑flow led value creation as priorities while retaining significant R&D investment of about INR 249 crore in Q3 FY26. Biocon’s biosimilars franchise is accelerating commercial traction with multiple regulatory wins (MHRA, EMA approvals) and launches; the company lists roughly 17 oncology assets and cites an approximately US$75+ billion addressable opportunity in oncology and immunology, reflecting deliberate pipeline focus. Financially, Q3 FY26 showed resilience: consolidated operating revenue of INR 4,173 crore (up 9% YoY), core EBITDA growth of 21% YoY to INR 1,221 crore, biosimilars EBITDA up 44% YoY, and a reported net profit recovery driven by favorable mix, higher‑margin prioritization and balance sheet simplification.
Over the past 52 weeks, Biocon Ltd has traded between a low of ₹331.00 and a high of ₹440.30. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Biocon Ltd has a market capitalization of approximately 68,621.13. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Biocon Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 177.96 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 68,621.13 Cr, Biocon Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Biocon Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Biocon Ltd is 177.96. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Biocon said its partner Duopharma secured multiple Malaysia MoH insulin contracts worth over MYR 225 million, with Biocon’s Malaysia unit supplying three insulin types for distribution.
Biocon says it aims to become the world’s top insulin supplier within five years and target about 20% share of the global insulin market.
Kiran Mazumdar-Shaw said Biocon could become the number one insulin company in the world in five years, supported by scale and capacity investments.
Biocon said it aims to become the world’s number one insulin company within five years and is targeting 20% share of the global insulin market.
Bearish
3
Neutral
7
Bullish
4
Bearish
5
Neutral
7
Bullish
34
Bearish
2
Neutral
0
Bullish
30
Order Win/Contract
Biocon Ltd said partner Duopharma Biotech's subsidiary secured Malaysia MoH insulin contracts valued at over MYR 225 million; Biocon Sdn. Bhd. will supply human insulin (~ MYR 155.27 million, 3 years), insulin glargine (~ MYR 18 million, 2 years) and insulin aspart (~ MYR 52.5 million, 2 years).
Dividend
Biocon Ltd stated the Board recommended a final dividend of 10% (Re. 0.50 per equity share of face value Rs.5) for the Financial Year ended March 31, 2026, subject to AGM approval on August 06, 2026 (Record Date July 03, 2026), and communicated applicable TDS rates and documentation requirements to shareholders.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1535.50 | 89,182 Cr | 25.45 | 2.35 | 0.26 | 9.25 | 11.76 | 5.99 | ||
1480.80 | 80,000 Cr | 90.01 | 15.09 | 0.13 | 16.77 | 16.14 | 8.47 | ||
423.35 | 68,621 Cr | 177.96 | 2.02 | 0.12 | 1.14 | 3.64 | 0.58 | ||
5411.25 | 64,700 Cr | 28.11 | 4.68 | 0.98 | 16.66 | 18.61 | 11.27 | ||
2180.65 | 61,538 Cr | 45.19 | 5.85 | 0.11 | 28.08 | 32.70 | 6.84 | ||
25574.00 | 54,345 Cr | 35.02 | 11.38 | 1.86 | 32.51 | 42.54 | 23.87 | ||
1623.35 | 41,185 Cr | 36.09 | 5.11 | 0.37 | 14.15 | 18.58 | 9.63 | ||
| Median: 7 Co. | — | 1623.35 | 64,700 Cr | 36.09 | 5.11 | 0.26 | 16.66 | 18.58 | 8.47 |
Biocon is a fully integrated, innovation‑led biopharmaceutical company from India focused on biosimilars, complex biologics, interchangeable insulins, generic formulations, peptides (GLP‑1s) and research/CRDMO services through Syngene with global manufacturing and commercialization reach across North America, Europe and emerging markets.
The group is at an operational inflection: major capex is largely complete, operating leverage is beginning to play out, and management highlights margin expansion and cash‑flow led value creation as priorities while retaining significant R&D investment of about INR 249 crore in Q3 FY26.
Biocon’s biosimilars franchise is accelerating commercial traction with multiple regulatory wins (MHRA, EMA approvals) and launches; the company lists roughly 17 oncology assets and cites an approximately US$75+ billion addressable opportunity in oncology and immunology, reflecting deliberate pipeline focus.
Financially, Q3 FY26 showed resilience: consolidated operating revenue of INR 4,173 crore (up 9% YoY), core EBITDA growth of 21% YoY to INR 1,221 crore, biosimilars EBITDA up 44% YoY, and a reported net profit recovery driven by favorable mix, higher‑margin prioritization and balance sheet simplification.
Pharmaceuticals & Biotechnology
Pharmaceuticals
68,467 Cr
Low Risk
177.6
35.2
2.5
2.0
440.30
331.00
Sales CAGR
Profit CAGR
ROE
ROCE
